SCHEMBL4893116

SCHEMBL4893116

O=C(c1cc(Cl)c(OCc2ccccc2)c(Cl)c1)N1C=COC(C2=CC=CCC2)=C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
MRGPRX4 Q96LA9 3/20 0.33
GLRA1 P23415 2/20 0.33
FABP4 P15090 1/20 0.33
HPGD P15428 2/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
MITF O75030 1/20 0.32
TP53 P04637 1/20 0.32
XBP1 P17861 1/20 0.32
NFKB1 P19838 1/20 0.32
RAB9A P51151 1/20 0.32
NFKB2 Q00653 1/20 0.32
KMT2A Q03164 1/20 0.32
RELA Q04206 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
S1PR1 P21453 2/20 0.32
S1PR5 Q9H228 2/20 0.32
PRKX P51817 1/20 0.32
ACVR1 Q04771 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4898144 0.90 KDM4E (0.33) KDM4EMEN1NPC1RAB9AKMT2A
SCHEMBL4891026 0.90 TAOK1 (0.38) MRGPRX4GLRA1HPGDMEN1NPC1
SCHEMBL4902300 0.87 KMT2A (0.33) KMT2APLAU
SCHEMBL4895543 0.85 KDM4E (0.36) KDM4EMRGPRX4GLRA1FABP4HPGD
SCHEMBL4900143 0.82 KDM4E (0.37) KDM4EMRGPRX4GLRA1FABP4HPGD
SCHEMBL5012584 0.80 HSD11B1 (0.37)
SCHEMBL4899128 0.79 L3MBTL1 (0.34) KDM4EHPGDSMN1; SMN2ALDH1A1
SCHEMBL4900046 0.78 HSD11B1 (0.34) HPGDSMN1; SMN2LMNA
SCHEMBL4900291 0.77 TAS1R3 (0.37) KDM4EHPGDMEN1NPC1TP53
SCHEMBL4900204 0.76 SLC22A12 (0.38) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds NOD1, NLRP3, SLC10A1 KDM4E 2953/4885MRGPRX4 3901/4885GLRA1 3992/4885
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof NUDT1, NOD1, SLC28A1 KDM4E 3266/4885MRGPRX4 1552/4885GLRA1 2399/4885
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds NOD1, XDH, URB2 KDM4E 2773/4885MRGPRX4 3508/4885GLRA1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.